AB Science will present results from its Phase 3 AB07015 study in severe asthma at the 2020 American Thoracic Society International Conference

Paris, March 13 2020, 7.30am

AB Science to present results from its Phase 3 AB07015 study in severe asthma at the 2020 American Thoracic Society International Conference

Platform presentation will be included in a mini-symposium on
Late Breaking Clinical Trials in Airway Diseases being held on Monday, May 18, 2020

AB Science SA (Euronext - FR0010557264 - AB) today announced that an abstract reporting results from its Phase 3 AB07015 study on severe asthma uncontrolled by oral corticosteroids (OCS), has been selected for oral platform presentation at the upcoming American Thoracic Society (ATS) 2020 International Conference in Philadelphia, USA (May 15-20, 2020).

Pascal Chanez, Professor of Respiratory Diseases at Aix-Marseille University, France, will present key data from the positive Phase 3 study, AB07015, as part of a mini symposium session entitled ‘Late Breaking Clinical Trials in Airway Diseases’.

ATS is one of the world’s largest meetings for pulmonary medicine professionals and has been historically well-attended by key opinion leaders and decision-makers in asthma research and healthcare policy.

Pascal Chanez said: “Selection of this abstract for a platform presentation on late-breaking clinical trials at the upcoming annual ATS Conference in Philadelphia is an indication of the clinical relevance of study AB07015 and masitinib potential impact on the treatment landscape for severe asthma”.

Olivier Hermine (President of the Scientific Committee of AB Science and member of the Académie des Sciences in France) said: “Unlike the biologic that are suited for patients with severe asthma associated with high eosinophils only, masitinib is effective regardless of the eosinophil level. This is due to its mechanism of action which is more global. Biologics targets eosinophils to reduce their quantity, whereas masitinib target mast cells which play a central role in asthma. In addition masitinib target PDGF receptor that seems to play a role in airway remodeling”.

Details for the presentation are as follows:

Presentation Title:       Masitinib Significantly Decreases the Rate of Asthma Exacerbations in Patients with Severe Asthma Uncontrolled by Oral Corticosteroids: A Phase 3 Multicenter Study
Session Title:                 Mini Symposium on Late Breaking Clinical Trials in Airway Diseases (B93)
Date/Time:                    Monday May 18, 2020 2:15 PM - 4:15 PM